Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D).
John P KirwanAnita P CourcoulasDavid E CummingsAllison B GoldfineSangeeta R KashyapDonald C SimonsonDavid E ArterburnWilliam F GourashAshley H VernonJohn M JakicicMary Elizabeth PattiKathy WolskiPhilip R SchauerPublished in: Diabetes care (2022)
Three-year follow-up of the largest cohort of randomized patients followed to date demonstrates that metabolic/bariatric surgery is more effective and durable than medical/lifestyle intervention in remission of type 2 diabetes, including among individuals with class I obesity, for whom surgery is not widely used.
Keyphrases
- type diabetes
- bariatric surgery
- weight loss
- minimally invasive
- cardiovascular disease
- end stage renal disease
- coronary artery bypass
- metabolic syndrome
- glycemic control
- insulin resistance
- randomized controlled trial
- healthcare
- ejection fraction
- newly diagnosed
- chronic kidney disease
- disease activity
- prognostic factors
- open label
- surgical site infection
- peritoneal dialysis
- ulcerative colitis
- double blind
- clinical trial
- placebo controlled
- physical activity
- patient reported outcomes
- body mass index
- coronary artery disease
- weight gain
- systemic lupus erythematosus
- skeletal muscle
- high fat diet induced
- patient reported